Splitomicin

Splitomicin (Splitomycin) is a selective Sir2p inhibitor. Splitomicin inhibits NAD+-dependent HDAC activity of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast extract with an IC50 of 60 μM[1].

Product Specifications

CAS Number

[5690-03-9]

Product Name Alternative

Splitomycin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/splitomicin.html

Concentration

10mM

Purity

98.42

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1CCC2=C3C=CC=CC3=CC=C2O1

Molecular Formula

C13H10O2

Molecular Weight

198.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Bedalov A, et al. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci U S A. 2001 Dec 18;98 (26) :15113-8.|[2]Breitenstein A, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res. 2011 Feb 1;89 (2) :464-72.|[3]Ota H, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene. 2006 Jan 12;25 (2) :176-85.